These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31521180)

  • 21. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Antibodies against Intracellular Tumor Antigens.
    Trenevska I; Li D; Banham AH
    Front Immunol; 2017; 8():1001. PubMed ID: 28868054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Participation of L3T4 in T cell activation in the absence of class II major histocompatibility complex antigens. Inhibition by anti-L3T4 antibodies is a function both of epitope density and mode of presentation of anti-receptor antibody.
    Owens T; Fazekas de St Groth B
    J Immunol; 1987 Apr; 138(8):2402-9. PubMed ID: 2435798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.
    Lorenz FKM; Ellinger C; Kieback E; Wilde S; Lietz M; Schendel DJ; Uckert W
    Hum Gene Ther; 2017 Dec; 28(12):1158-1168. PubMed ID: 28950731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MM-GBSA binding free energy decomposition and T cell receptor engineering.
    Zoete V; Irving MB; Michielin O
    J Mol Recognit; 2010; 23(2):142-52. PubMed ID: 20151417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
    Lustgarten J; Waks T; Eshhar Z
    Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation.
    Campanelli R; Palermo B; Garbelli S; Mantovani S; Lucchi P; Necker A; Lantelme E; Giachino C
    Int Immunol; 2002 Jan; 14(1):39-44. PubMed ID: 11751750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural basis of T cell recognition.
    Garcia KC; Teyton L; Wilson IA
    Annu Rev Immunol; 1999; 17():369-97. PubMed ID: 10358763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coevolution of T-cell receptors with MHC and non-MHC ligands.
    Castro CD; Luoma AM; Adams EJ
    Immunol Rev; 2015 Sep; 267(1):30-55. PubMed ID: 26284470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.
    Spear TT; Riley TP; Lyons GE; Callender GG; Roszkowski JJ; Wang Y; Simms PE; Scurti GM; Foley KC; Murray DC; Hellman LM; McMahan RH; Iwashima M; Garrett-Mayer E; Rosen HR; Baker BM; Nishimura MI
    J Leukoc Biol; 2016 Sep; 100(3):545-57. PubMed ID: 26921345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing TCR for cancer immunotherapy.
    Voss RH; Kuball J; Theobald M
    Methods Mol Med; 2005; 109():229-56. PubMed ID: 15585925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
    Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
    Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.
    Saeed M; van Brakel M; Zalba S; Schooten E; Rens JA; Koning GA; Debets R; Ten Hagen TL
    Int J Nanomedicine; 2016; 11():955-75. PubMed ID: 27022262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.